read that latest imagion post and you have many answers

That post does give in layman's terms what that conference was all about with the imagion presentation.
The company states that the second cohort is running (the other patients we keep harping on about) and their trend for data is matching that of the first six. They are up and running.
Only six chosen because they only had the sufficient data needed to meet the requirements for a major medical conference.
Some other points of interest it states that MR is showing it has the potential to improve radiological evaluation thereby improving the standard of care for clinical assessments. Also to date MRX is showing a measurable signal that is indicating detectability but more data needed to secure this.
Its showing it can indicate normal vs tumor cells removing present imaging capability to identify a region of interest or suspicious lesion to yes it is a cancer.
So it looks very likely it does work and when they finish up with that positive proof they say they will go ahead and begin building those machines to scan next patients as per a normal scan procedure but with those biopsies.